mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging 2018View this Special Issue
Gankyrin Drives Malignant Transformation of Gastric Cancer and Alleviates Oxidative Stress via mTORC1 Activation
Gastric cancer, as a malignant epithelial tumor, is a major health threat leading to poor overall survival and death. It is usually diagnosed at an advanced stage due to asymptomatic or only nonspecific early symptoms. The present study demonstrated that gankyrin contributes to the early malignant transformation of gastric cancer and can be selected to predict the risk of gastric cancer in those patients harboring the precancerous lesions (dysplasia and intestinal metaplasia). In addition, a new insight into gastric cancer was provided, which stated that gankyrin alleviates oxidative stress via mTORC1 pathway activation. It can potentiate the mTORC1 by PGK1-AKT signaling that promotes the tumor process, and this phenomenon is not completely consistent with the previous report describing colorectal cancer.
Gankyrin (also named p28, p28GANK, or PSMD10) acts as a molecular chaperone during the assembly of the 26S proteasome, specifically the 19S regulatory complex [1–3], and is commonly overexpressed in human malignancies [4–9]. It is involved in the negative regulation of pRB1 and p53/TP53 to execute the oncoprotein function [3, 10]. The competitive binding with CDKN2A triggers gankyrin to regulate the CDK4-mediated phosphorylation and further proteasomal degradation of RB1 [11, 12]. Similarly, gankyrin binds to MDM2, a major E3 ubiquitin ligase for p53, and increases the MDM2-mediated mono- or polyubiquitination of p53 in order to exhibit the antiapoptotic activity in the cells that were injured by DNA-damaging agents [4, 10, 12, 13]. Moreover, oxidative stress disorder is also speculated to be involved in the development of various human diseases including cancer [14, 15]. In hepatocellular carcinoma, overexpressed gankyrin inhibits the proteasomal degradation of Nrf2 by blocking the interaction between Nrf2 and Keap1 and plays an antioxidative role via the feedback regulation of Nrf2 . Beyond the function of mediating protein degradation, gankyrin can directly bind to the NF-κB component RelA and accelerate its chromosomal region maintenance-1- (CRM-1-) mediated nuclear export in hepatocellular carcinoma . This phenomenon might be attributed to the gankyrin-mediated attenuation of the acetylation of RelA and its retention in the cytoplasm to suppress NF-κB transactivation . This evidence reveals that gankyrin is involved in the multiple biological and physiological processes in cells and contributes to the development of cancer. The most recent data from our group showed that gankyrin mediates TSC2 for degradation and regulates mTOR signaling via a p53-independent pathway in colorectal cancer . However, whether gankyrin plays an analogical function or regulatory role in the cell signaling pathway in gastric cancer is yet an enigma.
Gastric (stomach) cancer is the third leading cause of deaths from cancer accounting for 7% of the cases and 9% deaths after lung and liver cancer . It is primarily caused by Helicobacter pylori infection, which accounts for >60% of the cases [20, 21], smoking , diet , and genetics [23, 24]. Due to the absence of early typical clinical signs, gastric cancer has often been diagnosed at an advanced stage and may have occurred as distant metastasis before the symptoms onset. These manifestations might be the primary cause of the relatively poor prognosis of the disease . However, increasing evidence has revealed that gankyrin is a promising target for the diagnosis and treatment of several cancers [8, 26–29]. Nevertheless, compelling proofs to describe and illustrate the functional role or clinical significance of gankyrin in the development of gastric cancer are yet lacking.
Gastric intestinal metaplasia (GIM) and dysplasia, precursor lesions to and gastric cancer, are usually observed in the milieu of long-standing nonatrophic gastritis (NAG) and chronic atrophic gastritis (CAG) [30, 31]. Herein, we demonstrated that gankyrin is transcriptionally activated in tissue cells since patients harbored chronic atrophic gastritis, precancerous lesion (GIM and dysplasia), or gastric cancer and, thus, might be a preeminent candidate target for the early diagnosis of gastric cancer. In addition, we also found that gankyrin restricted the oxidative stress by stimulating the mTORC1 signaling in gastric cancer.
2. Materials and Methods
2.1. Tissues and Immunohistochemistry
Deidentified tissues from 262 patients were included. 77 malignant infiltrating gastric cancer tissues and paired noncancerous tissues were collected from the hospital and developed into tissue array by OUTDO Biotech (Shanghai, China). 120 noncancerous tissues, including nonatrophic gastritis (NAG), chronic atrophic gastritis (CAG), CAG with intestinal metaplasia (IM), and CAG with dysplasia (dys) gastric tissue, were acquired by endoscopy, 30 cases for each group. 65 gastric cancer samples with complete follow-up data were collected for survival analysis. Follow-up time and survival time were calculated from the day of the operation to the end of the follow-up or the date of death due to recurrence and metastasis. The study protocols were approved by the SJTUSM (Shanghai Jiao Tong University School of Medicine) Ethics Committee. All procedures adhere to the BRISQ Guidelines reporting research on human biospecimens. Immunohistochemical detection of gankyrin was performed using a streptavidin-biotin complex method as described previously . For quantitative analysis, a histoscore (H-score) was calculated using Aperio Scan Scope systems (Vista, CA, USA) as previously described, by multiplying the intensity score and the fraction score, producing a total range of 0–300 . Tissue sections were examined and scored separately by two independent investigators blinded to the clinicopathologic data.
2.2. Cell Culture and Reagents
The gastric cancer cell lines, MKN45 and MKN74, were purchased from the Shanghai Institute for Biological Sciences (SIBS, Shanghai, China) and cultured in RPMI 1640 medium (HyClone, Los Angeles, CA, USA) containing 10% fetal bovine serum (FBS; HyClone) and 100 U/mL penicillin/streptomycin under conditions of 5% CO2 and humidified air at 37°C. The lentiviral pCDH-EF1-MCS-T2A-copGFP gankyrin plasmid was constructed, packed, and purified by Sunbio (Shanghai, China).
2.3. MTT Assay
The activity of MKN45 and MKN74 cells overexpressing gankyrin or vector control (NC) was determined by MTT assay. Briefly, the cells were seeded in quintuplicate in 96-well culture plates and cultured for up to 96 h, followed by an addition of 20 μL of 5 mg/mL MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; Sigma-Aldrich, St. Louis, MO, USA) solution per well. After incubation for 4 h at 37°C, the supernatant was replaced with 100 μL DMSO. The absorbance per well was measured by a Microculture Plate Reader at 570 nm and 630 nm after 20 min agitation at room temperature. The data represent the means ± standard deviation (SD) from three independent triplicate experiments.
2.4. Colony Forming Assay
Cells were seeded in triplicate in 12-well plates to form colonies for up to 7–10 days. The medium containing selective antibiotics was replaced every 3–5 days. The colonies were stained with methylene blue and counted. Data represent the means ± SD from three independent experiments performed in triplicate.
2.5. Soft Agar Assay
The anchorage-independent growth of MKN45 and MKN74 cells overexpressing gankyrin or NC was determined by soft agar assays. Briefly, 0.7% basal-layer agar was prepared with 1.4% low-melting-point agarose and 2 × cell medium (1 : 1, ). 1 mL of basal layer agar was added to each well of a 6-well plate. The exponentially growing cells were harvested by trypsinization to 5000 cells/mL single-cell suspension. 0.35% top-layer agar was prepared with 0.7% low-melting point agarose and 2 × cell medium (1 : 1, ). Subsequently, 1 mL top-layer agar was blended with 100 μL single-cell suspension/well (500 cells/well). The cells were incubated for up to 1–2 weeks at 37°C after solidification at room temperature. Cultures were stained with p-iodonitrotetetrazolium violet (Sigma-Aldrich) for 2 h and then inspected and photographed using a MiniCount Colony Counter. The colonies containing more than 50 cells were counted and imaged. The data represent the means ± SD from three independent experiments in triplicate.
2.6. Transwell Invasion Assay
The cell suspension was prepared in a blank culture medium containing 5 × 105 cells/mL for 24-well invasion chambers. The upper surface of the membrane was scrubbed carefully with a cotton swab to remove the remaining cells, and Matrigel matrix after chambers was incubated for up to 16–18 h at 37°C. The cells on the lower surface of the membranes were fixed with 100% methanol and stained with 0.5% crystal violet. The invaded cells were imaged and counted in several fields under the microscope at approximately 40x–100x magnification. Data represent the means ± SD from three independent triplicate experiments.
Total protein was extracted by RIPA lysis Buffer (Sigma-Aldrich) and subjected to immunoblotting as described previously . Reagents were obtained from the following sources: antibodies for gankyrin (Santa Cruz, Dallas, Texas, USA); antibodies for PGK1 (Abcam, Cambridge, MA, USA); antibodies for p-S6K (T398), S6K1, S6, p-S6 (S235/236), mTOR, p-AKT (S473), AKT, p-4E-BP1 (T37/46), and 4E-BP1; and HRP-conjugated secondary antibody (Cell Signaling Technology; Danvers, MA, USA).
2.8. Reactive Oxygen Species (ROS) Fluorescent Probe
MKN45 cells overexpressing gankyrin or NC were treated with DMSO or 10 nM rapamycin for 1 h. Oxidative stress of treated cells was determined by 2,7-dichlorodihydrofluorescein diacetate (H2DCF-DA) and dihydroethidium (DHE) that indicate the level of ROS. DHE or H2DCF-DA probe solution was diluted to an appropriate concentration by culture medium, and the cell culture medium was replaced by the diluted probe solution. After incubation at room temperature for 10–90 min in the dark light, the cells were washed with fresh solution and imaged by green or blue filters using a fluorescence microscope.
2.9. Statistical Analysis
Statistical analysis was performed with the SAS for Windows and GraphPad Prism V6 (GraphPad Prism Inc., USA); was considered to be statistically significant. The results were expressed as the mean ± SD. The correlation between gankyrin expression and clinicopathological parameters was analyzed by Fisher’s exact test. The comparisons were analyzed using Student’s -test. The correlation between gankyrin and PGK1 expressions was tested by Pearson’s correlation analysis. The cancer-specific survival curves were estimated by Kaplan-Meier plots and log-rank test.
3.1. Gankyrin Contributes to the Early Malignant Behavior of Gastric Cancer
To explore the relationship between gankyrin and the risk of harboring gastric cancer, we investigated the expression of gankyrin in a large panel of gastric precancerous and cancerous clinical samples. Compared to nonatrophic gastritis (NAG) tissue, the expression of gankyrin was elevated in chronic atrophic gastritis (CAG) and significantly higher in CAG with intestinal metaplasia (CAG + Im) or dysplasia (CAG + dys) (Figures 1(a) and 1(b) and Table 1). The gankyrin staining-positive rate and median H-score in dysplasia (positive rate = 90.00%, median H-score = 150) were similar to those in gastric cancer tissues (positive rate = 92.78%, median H-score = 145). Since the CAG-metaplasia/dysplasia-cancer sequence represents the process by which most gastric cancers arise, the data indicated that gankyrin overexpression is involved in the very early stage of gastric carcinogenesis; this finding was consistent with that in human colorectal precancerous and cancerous lesions . In tissue array analysis, the overall gankyrin staining was stronger in tumors (median H-score = 185) as compared to the paired noncancerous tissues (median H-score = 140) (Figures 1(c) and 1(d)). This phenomenon was further validated in the published dataset (GEO access number: GSE26942), wherein gastric cancer tissues showed significantly higher gankyrin mRNA level as compared to the noncancerous tissues () (Figure 1(e)). In the tissue array comprising 77 cases, gankyrin overexpression was associated with lymph node metastasis (), distant metastasis (), and vascular invasion () (Table 2). The log-rank test revealed that high gankyrin expression was significantly correlated with poor survival (, ) (Figure 1(f)). Taken together, gankyrin contributes to the early malignant behavior of gastric cancer.
3.2. Gankyrin Promotes the Oncogenic Properties of Gastric Cancer Cell
To inspect the phenotypes induced by gankyrin in gastric cancer cells, we firstly identified the basal levels of human normal gastric epithelial cell (GSE-1) and several gastric cancer cell lines using Western blot analysis and the results revealed that high gankyrin expression was observed in all cancer cell lines, but it was undetectable in GES-1 (Figure 2(a)). To explore the function of gankyrin in gastric cancer development, MKN74 (low-gank expression) and MKN45 (high-gank expression) cells were chosen to establish the gankyrin overexpression cell lines. The MTT assays showed that overexpressed gankyrin significantly accelerated the cell growth as compared to that by background expression (Figure 2(b)). Both foci formation assay (Figures 2(c) and 2(d)) and soft agar assay (Figures 2(e) and 2(f)) measured the anchorage-dependent or anchorage-independent cell growth and revealed that gankyrin promoted the characteristics of transformed cells with marked differences in either MKN74 or MKN45 cells. To assess the gankyrin-mediated invasion ability of gastric cancer cell, the Transwell trails showed that gankyrin significantly facilitated the motility and invasiveness of cancer cells as compared to the negative controls (Figures 2(g) and 2(h)). Taken together, gankyrin possesses the oncogenic properties to promote the malignant behavior of gastric cancer cells.
3.3. Gankyrin Potentiates mTORC1 Signaling via PGK1/AKT
In a previous report, we showed that gankyrin significantly enhanced the mTOR activity in colorectal cancer (CRC) through targeting TSC2 for degradation, independent of AKT signaling . Intriguingly, gankyrin can also activate the mTORC1 signaling pathway with enhanced the levels of phosphorylated S6K1 and 4E-BP1 in gastric cancer cells (Figure 3(a)). Unlike that in CRC, gankyrin activated the AKT signaling and its upstream regulator PGK1 in gastric cancer as assessed by Western blot analysis (Figure 3(a)); this phenomenon was in agreement with the studies, wherein PGK1 activates AKT/mTOR in lung cancer  and regulates autophagy to promote tumorigenesis via the mTOR pathway . Moreover, the mRNA level of gankyrin and PGK1 was found to be correlated in 414 gastric cancer samples according to the TCGA cancer genome database by Pearson’s correlation analysis (Figure 3(b)). Taken together, gankyrin can potentiate the mTORC1 signaling via a PGK1-AKT pathway in gastric cancer.
3.4. Gankyrin Alleviates Oxidative Stress in Gastric Cancer Cell by Activating mTORC1
Oxidative stress may be the cause of direct damage to DNA and, therefore, mutagenic . It may also suppress apoptosis and promote cancer cell proliferation, invasiveness, and metastasis . The production of reactive oxygen and nitrogen species increased by Helicobacter pylori infection in the stomach is also crucial for the development of gastric cancer [25, 35]. To investigate whether gankyrin affected the process of oxidative stress, the mTORC1 signaling was successfully suppressed using rapamycin in both MKN45 and MKN74 cells with or without gankyrin overexpression (Figure 4(a)). Representative DHE staining and quantification data showed that overexpressed gankyrin significantly inhibited the reactive oxidative species (ROS) as compared to the negative control (Figures 4(b), 1st and 3rd panels, and 4(c)). However, ROS was sustained by rapamycin treatments either with or without gankyrin overexpression (Figures 4(b), 2nd and 4th panels, and 4(c)), which was in agreement with DCF staining and quantification data (Figures 4(a) and 4(e)). Altogether, gankyrin can alleviate the oxidative stress by activating mTORC1 in the gastric cancer cell.
Gastric cancer, as a malignant epithelial tumor, continues to be a major health threat related to death and poor overall survival > 5 years in both sexes worldwide . In the early stages, gastric cancer either is often asymptomatic or causes only nonspecific symptoms, which might be associated with indigestion, abdominal discomfort, anorexia, or a burning sensation. Without the endoscope detection, the occurrence of gastric cancer at an early stage cannot be diagnosed easily for a timely treatment . Gastric carcinogenesis is a multistep process that develops from chronic gastritis, atrophy, gastric intestinal metaplasia (GIM), and dysplasia and finally leads to gastric cancer . GIM and dysplasia are speculated as the premalignant stage of gastric cancer in a population of patients [37, 38], guiding the appropriate clinical recommendations for reducing the risk of gastric cancer .
Herein, we revealed that Gankyrin, an oncoprotein and a potential therapeutic target in multiple cancer diseases [7, 8, 18, 24, 26, 27], was a great biomarker for the early diagnosis of gastric cancer according to the detection and analysis of its expression in a large cohort of gastric precancerous and cancerous clinical samples (Figure 1). The significantly enhanced expression of gankyrin in CAG with intestinal metaplasia or dysplasia indicated an increased risk of gastric carcinoma. Moreover, high level of gankyrin expression in gastric tumor samples or cell lines demonstrated its role in promoting the process of gastric cancer, including tumor growth, metastasis, or vascular invasion in vivo (Figure 1) and in vitro (Figure 2); also, it was significantly correlated with poor survival in clinics (Figure 1(f)). In addition to environmental risk factors (infection, smoking, or diets), a number of molecular and genetic aberrations also contribute to gastric carcinogenesis, including changes in p53, KRAS, CDH1, cyclin E, Her2, and MET . The genetic alteration in p53 leading to the development of gastric cancer is also seen in H. pylori-associated conditions such as chronic gastritis, intestinal metaplasia, and dysplasia [41–43]. Intriguingly, p53 can also be negatively regulated by gankyrin in multiple cancer types [3, 10], which is similar to the observation in the current study that gankyrin involves the precancerous lesions of gastric cancer. To compare the oncogenic properties between cell lines, MKN45 (poorly differentiated adenocarcinoma) with high-gank expression seemed showing higher proliferation abilities than MKN74 (highly differentiated adenocarcinoma) with low-gank expression (Figures 2(a)–2(d)), which also hinted that gankyrin might promote the process of gastric cancer development. Thus, the data strongly suggested that gankyrin contributes to early malignant transformation and later processes of gastric cancer (Figures 1 and 2).
In a previous report, we demonstrated that gankyrin regulates the mTORC1 signaling pathway in CRC via a PI3K/AKT-independent and TSC-dependent mechanism . On the other hand, the AKT activation was found to be involved in the gankyrin-induced mTORC1 signaling according to our findings in gastric cancer (Figure 3(a)), which indicated that gankyrin might be associated with or regulated by an alternative molecule to potentiate the mTORC1 signaling pathway. The analysis of the TCGA cancer genome database also revealed that the mRNA expression of gankyrin was clinically correlated to PGK1, an upstream protein kinase of AKT (Figure 3(b)). This evidence introduced a novel insight into gankyrin biology in gastric cancer. However, additional studies are essential to support that gankyrin activates PGK1/AKT signaling to enhance the mTORC1 activation. High ROS levels leading to oxidative stress limit cancer cell survival during certain windows of cancer initiation and progression [44, 45]. Recently, it has been reported that overexpressed gankyrin amplifies the antioxidant capacity of HCC cells, reduces oxidative stress-induced mitochondrial damage, inhibits apoptosis, and promotes the development of HCC . Consistently, the present study demonstrated that gankyrin can significantly impede ROS through the activation of mTORC1 signaling in gastric cancer (Figure 4). Moreover, we found that gankyrin affected not only the production of hydrogen peroxide (Figures 4(d) and 4(e)) but also the superoxide anion (Figures 4(b) and 4(c)), which supplied an interesting cue that gankyrin may exert its function through superoxide anion. However, it still needs further study on it. Therefore, gankyrin might also exhibit effects of accelerating the cancer process by regulating oxidative stress and maintaining cell homeostasis through the mTORC1 signaling pathway.
In conclusion, the current study revealed that increased gankyrin expression could be a risk factor of harboring gastric cancer. It potentially drove malignant transformation and behaviors of gastric cancer cell, as well as alleviated oxidative stress through the mTORC1 pathway. These characteristics provide a new insight into gankyrin biology with respect to gastric cancer.
The datasets analyzed during the current study are available in the TCGA (https://cancergenome.nih.gov/), GEO (https://www.ncbi.nlm.nih.gov/gds), PrognoScan dataset (http://www.prognoscan.org/), and HPA dataset (http://www.proteinatlas.org/). All data generated during this study are included in this article.
Conflicts of Interest
All authors declare that they have no potential conflicts of interests.
Bo Huang and Weiyang Cai are the co-first authors.
This study was supported by the grants from the National Natural Science Foundation of China (grant numbers 81672354, 81672708, and 81572796) and the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine (grant number 20172017).
B. Padmanabhan, N. Adachi, K. Kataoka, and M. Horikoshi, “Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6,” The Journal of Biological Chemistry, vol. 279, no. 2, pp. 1546–1552, 2004.View at: Publisher Site | Google Scholar
S. Krzywda, A. M. Brzozowski, R. al-Safty et al., “Crystallization of gankyrin, an oncoprotein that interacts with CDK4 and the S6b (rpt3) ATPase of the 19S regulator of the 26S proteasome,” Acta Crystallographica. Section D, Biological Crystallography, vol. 59, Part 7, no. 7, pp. 1294-1295, 2003.View at: Publisher Site | Google Scholar
S. Krzywda, A. M. Brzozowski, H. Higashitsuji et al., “The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53,” The Journal of Biological Chemistry, vol. 279, no. 2, pp. 1541–1545, 2004.View at: Publisher Site | Google Scholar
H. Higashitsuji, H. Higashitsuji, K. Itoh et al., “The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53,” Cancer Cell, vol. 8, no. 1, pp. 75–87, 2005.View at: Publisher Site | Google Scholar
Y. Liu, J. Zhang, W. Qian et al., “Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasis,” PLoS One, vol. 9, no. 4, article e95043, 2014.View at: Publisher Site | Google Scholar
Y. H. Kim, J. H. Kim, Y. W. Choi et al., “Gankyrin is frequently overexpressed in breast cancer and is associated with ErbB2 expression,” Experimental and Molecular Pathology, vol. 94, no. 2, pp. 360–365, 2013.View at: Publisher Site | Google Scholar
L. Valanejad, K. Lewis, M. Wright et al., “FXR-gankyrin axis is involved in development of pediatric liver cancer,” Carcinogenesis, vol. 38, no. 7, pp. 738–747, 2017.View at: Publisher Site | Google Scholar
M. M. Riahi, N. S. Sistani, P. Zamani, K. Abnous, and K. Jamialahmadi, “Correlation of gankyrin oncoprotein overexpression with histopathological grade in prostate cancer,” Neoplasma, vol. 64, no. 5, pp. 732–737, 2017.View at: Publisher Site | Google Scholar
A. Umemura, Y. Itoh, K. Itoh et al., “Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma,” Hepatology, vol. 47, no. 2, pp. 493–502, 2008.View at: Publisher Site | Google Scholar
H. Higashitsuji, Y. Liu, R. J. Mayer, and J. Fujita, “The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation,” Cell Cycle, vol. 4, no. 10, pp. 1335–1337, 2005.View at: Publisher Site | Google Scholar
J. Li and M. D. Tsai, “Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb,” Biochemistry, vol. 41, no. 12, pp. 3977–3983, 2002.View at: Publisher Site | Google Scholar
S. Dawson, H. Higashitsuji, A. J. Wilkinson, J. Fujita, and R. J. Mayer, “Gankyrin: a new oncoprotein and regulator of pRb and p53,” Trends in Cell Biology, vol. 16, no. 5, pp. 229–233, 2006.View at: Publisher Site | Google Scholar
G. Lozano and G. P. Zambetti, “Gankyrin: an intriguing name for a novel regulator of p53 and RB,” Cancer Cell, vol. 8, no. 1, pp. 3-4, 2005.View at: Publisher Site | Google Scholar
G. Bhattarai, Y. H. Lee, N. H. Lee, J. S. Yun, P. H. Hwang, and H. K. Yi, “C-myb mediates inflammatory reaction against oxidative stress in human breast cancer cell line, MCF-7,” Cell Biochemistry and Function, vol. 29, no. 8, pp. 686–693, 2011.View at: Publisher Site | Google Scholar
C. Yang, Y. X. Tan, G. Z. Yang et al., “Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma,” The Journal of Experimental Medicine, vol. 213, no. 5, pp. 859–875, 2016.View at: Publisher Site | Google Scholar
Y. Chen, H. H. Li, J. Fu et al., “Oncoprotein p28GANK binds to RelA and retains NF-κB in the cytoplasm through nuclear export,” Cell Research, vol. 17, no. 12, pp. 1020–1029, 2007.View at: Publisher Site | Google Scholar
Y. B. Ren, T. Luo, J. Li et al., “p28GANK associates with p300 to attenuate the acetylation of RelA,” Molecular Carcinogenesis, vol. 54, no. 12, pp. 1626–1635, 2015.View at: Publisher Site | Google Scholar
X. Qin, X. Wang, F. Liu et al., “Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer,” Cancer Letters, vol. 376, no. 1, pp. 83–94, 2016.View at: Publisher Site | Google Scholar
R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” Lancet, vol. 380, no. 9859, pp. 2095–2128, 2012.View at: Publisher Site | Google Scholar
A. H. Chang and J. Parsonnet, “Role of bacteria in oncogenesis,” Clinical Microbiology Reviews, vol. 23, no. 4, pp. 837–857, 2010.View at: Publisher Site | Google Scholar
C. A. Gonzalez, N. Sala, and T. Rokkas, “Gastric cancer: epidemiologic aspects,” Helicobacter, vol. 18, Supplement 1, pp. 34–38, 2013.View at: Publisher Site | Google Scholar
E. Theodoratou, M. Timofeeva, X. Li, X. Meng, and J. P. A. Ioannidis, “Nature, nurture, and cancer risks: genetic and nutritional contributions to cancer,” Annual Review of Nutrition, vol. 37, no. 1, pp. 293–320, 2017.View at: Publisher Site | Google Scholar
V. E. Strong, S. Gholami, M. A. Shah et al., “Total gastrectomy for hereditary diffuse gastric cancer at a single center: postsurgical outcomes in 41 patients,” Annals of Surgery, vol. 266, no. 6, pp. 1006–1012, 2017.View at: Publisher Site | Google Scholar
C. Langner, “Hereditary gastric and pancreatic cancer,” Pathology, vol. 38, no. 3, pp. 164–169, 2017.View at: Publisher Site | Google Scholar
M. Venerito, G. Nardone, M. Selgrad, T. Rokkas, and P. Malfertheiner, “Gastric cancer--epidemiologic and clinical aspects,” Helicobacter, vol. 19, Supplement 1, pp. 32–37, 2014.View at: Publisher Site | Google Scholar
P. Zamani, M. Matbou Riahi, A. A. Momtazi-Borojeni, and K. Jamialahmadi, “Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 46, no. 7, pp. 1301–1313, 2017.View at: Publisher Site | Google Scholar
C. Wang and L. Cheng, “Gankyrin as a potential therapeutic target for cancer,” Investigational New Drugs, vol. 35, no. 5, pp. 655–661, 2017.View at: Publisher Site | Google Scholar
W. P. Wang, X. L. Yan, W. M. Li et al., “Clinicopathologic features and prognostic implications of gankyrin protein expression in non-small cell lung cancer,” Pathology, Research and Practice, vol. 211, no. 12, pp. 939–947, 2015.View at: Publisher Site | Google Scholar
J. A. Hwang, H. M. Yang, D. P. Hong et al., “Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma,” Oncotarget, vol. 5, no. 19, pp. 9065–9078, 2014.View at: Publisher Site | Google Scholar
T. H. Malik, M. Y. Sayahan, H. A. al Ahmed, and X. Hong, “Gastric intestinal metaplasia: an intermediate precancerous lesion in the cascade of gastric carcinogenesis,” Journal of the College of Physicians and Surgeons, vol. 27, no. 3, pp. 166–172, 2017.View at: Google Scholar
P. Granelli, L. Bonavina, F. Zennaro, A. Segalin, and C. Siardi, “Intestinal metaplasia: what is its role in gastric carcinogenesis?” Minerva Gastroenterologica e Dietologica, vol. 40, no. 2, pp. 67–77, 1994.View at: Google Scholar
T. Yu, Y. Zhao, Z. Hu et al., “MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway,” Cancer Research, vol. 77, no. 21, pp. 5782–5794, 2017.View at: Publisher Site | Google Scholar
X. Qian, X. Li, and Z. Lu, “Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis,” Autophagy, vol. 13, no. 7, pp. 1246-1247, 2017.View at: Publisher Site | Google Scholar
B. Halliwell, “Oxidative stress and cancer: have we moved forward?” The Biochemical Journal, vol. 401, no. 1, pp. 1–11, 2007.View at: Publisher Site | Google Scholar
O. Handa, Y. Naito, and T. Yoshikawa, “Redox biology and gastric carcinogenesis: the role of helicobacter pylori,” Redox Report, vol. 16, no. 1, pp. 1–7, 2013.View at: Publisher Site | Google Scholar
P. Correa, “Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society award lecture on cancer epidemiology and prevention,” Cancer Research, vol. 52, no. 24, pp. 6735–6740, 1992.View at: Google Scholar
R. Pittayanon, R. Rerknimitr, N. Klaikaew et al., “The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up,” Alimentary Pharmacology & Therapeutics, vol. 46, no. 1, pp. 40–45, 2017.View at: Publisher Site | Google Scholar
A. D. Spence, C. R. Cardwell, Ú. C. McMenamin et al., “Adenocarcinoma risk in gastric atrophy and intestinal metaplasia: a systematic review,” BMC Gastroenterology, vol. 17, no. 1, p. 157, 2017.View at: Publisher Site | Google Scholar
A. Y. Choi, L. L. Strate, M. C. Fix et al., “Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population,” Gastrointestinal Endoscopy, vol. 87, no. 4, pp. 1023–1028, 2018.View at: Publisher Site | Google Scholar
H. I. Grabsch and P. Tan, “Gastric cancer pathology and underlying molecular mechanisms,” Digestive Surgery, vol. 30, no. 2, pp. 150–158, 2013.View at: Publisher Site | Google Scholar
N. Deng, L. K. Goh, H. Wang et al., “A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets,” Gut, vol. 61, no. 5, pp. 673–684, 2012.View at: Publisher Site | Google Scholar
S. Sue, W. Shibata, and S. Maeda, “Helicobacter pylori-induced signaling pathways contribute to intestinal metaplasia and gastric carcinogenesis,” BioMed Research International, vol. 2015, Article ID 737621, 9 pages, 2015.View at: Publisher Site | Google Scholar
B. A. Salih, Z. Gucin, and N. Bayyurt, “A study on the effect of Helicobacter pylori infection on p53 expression in gastric cancer and gastritis tissues,” Journal of Infection in Developing Countries, vol. 7, no. 9, pp. 651–657, 2013.View at: Publisher Site | Google Scholar
J. G. Gill, E. Piskounova, and S. J. Morrison, “Cancer, oxidative stress, and metastasis,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 81, pp. 163–175, 2017.View at: Publisher Site | Google Scholar
M. J. Vallejo, L. Salazar, and M. Grijalva, “Oxidative stress modulation and ROS-mediated toxicity in cancer: a review on in vitro models for plant-derived compounds,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 4586068, 9 pages, 2017.View at: Publisher Site | Google Scholar